Protalex Provides Update on US and EU Studies of PRTX-100 to Treat Immune Thrombocytopenia (Protalex Inc)
(WorldNews Health)

(Source: Protalex Inc) Expanding Number of Clinical Sites in US and EU; Underscoring Growing Interest in PRTX-100 among Clinical Investigators FLORHAM PARK, N.J.--(BUSINESS WIRE)-- Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, today provides an update on its U.S. Phase 1/2 and European Phase 1b studies of PRTX-100 in adults with persistent, chronic Immune Thrombocytopenia (ITP). PRTX-100, Protalex`s lead drug candidate, is a highly-purified form of Staphylococcal protein A (SpA) and is the subject of ongoing clinical development in ITP and rheumatoid arthritis (RA). PRTX-100 has been granted Orphan Drug Designation in the U.S. and in Europe for the treatment of...